Basel (Switzerland)/Mannheim (Germany) – November 4, 2022:
VAXIMM AG announces that all shares of the company have been transferred from the legacy investors (BB Biotech Ventures, BioMed Partners, CMS, M Ventures, NEC and Sunstone Capital) to BCM Europe AG, based in Zug, Switzerland, effective 4 November 2022. In the course of this, all previous management board, executive board and board of directors mandates were resigned.
Ralf Kubli becomes Managing Director of VAXIMM GmbH in Mannheim. At VAXIMM AG in Basel, Peter Hwang and Ralf Kubli were elected as members of the Board of Directors.
The business activities of VAXIMM will be continued.